Loading clinical trials...
Loading clinical trials...
Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
Conditions
Interventions
Regorafenib
Locations
1
Spain
Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Madrid, Spain
Start Date
June 1, 2014
Primary Completion Date
February 1, 2016
Completion Date
February 1, 2016
Last Updated
August 1, 2017
NCT06662786
NCT06663319
NCT05239741
NCT07112170
NCT07115914
NCT06925984
Lead Sponsor
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions